**REGISTERED COMPANY NUMBER: 07227937 (England and Wales) REGISTERED CHARITY NUMBER: 1136413** 

## **REPORT OF THE TRUSTEES AND** 

**UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2024** 

## **FOR** 

## **HEARTBURN CANCER UK** 

Hopper Williams & Bell Limited Chartered Accountants Highland House Mayflower Close Chandler's Ford Eastleigh Hampshire SO53 4AR 



## **Heartburn Cancer UK** 

# **ANNUAL REPORT & FINANCIAL STATEMENT FY2023/2024** 



**HEARTBURN CANCER UK** 

**CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2024** 

|||**Page**||
|---|---|---|---|
|**Reference and Administrative Details**||1||
|**Chairman's Report**||2||
|**Report of the Trustees**|3|to|11|
|**Statement of Trustees' Responsibilities**||12||
|**Independent Examiner's Report**||13||
|**Statement of Financial Activities**||14||
|**Balance Sheet**|15|to|16|
|**Notes to the Financial Statements**|17|to|27|





**HEARTBURN CANCER UK** 

**REFERENCE AND ADMINISTRATIVE DETAILS FOR THE YEAR ENDED 30 APRIL 2024** 

|**TRUSTEES**|Professor R C Fitzgerald|
|---|---|
||Ms B A Huntingdon|
||W Mathers|
||Mrs M E McCord|
||Dr O J Stovin|
||T Thornton-Jones (resigned 1.9.2023)|
||T J Underwood (resigned 6.6.2024)|
||M J C Farrier (appointed 1.11.2023)|
||Ms J Stevenson Timini (appointed 1.12.2023)|
||Professor S Markar (appointed 25.7.2024)|
|**REGISTERED OFFICE**|Grove House|
||Lutyens Close|
||Chineham Court|
||Basingstoke|
||Hampshire|
||RG24 8AG|
|**REGISTERED COMPANY**|07227937 (England and Wales)|
|**NUMBER**||
|**REGISTERED CHARITY**|1136413|
|**NUMBER**||
|**INDEPENDENT EXAMINER**|Hopper Williams & Bell Limited|
||Chartered Accountants|
||Highland House|
||Mayflower Close|
||Chandler's Ford|
||Eastleigh|
||Hampshire|
||SO53 4AR|



Page 1 



**HEARTBURN CANCER UK** 

**CHAIRMAN'S REPORT FOR THE YEAR ENDED 30 APRIL 2024** 

## **Welcome – a message from our chair and founder Mimi McCord** 

My husband Mike suffered from persistent heartburn all his adult life. I would buy antacids regularly in our weekly shop and think nothing of it until the day a piece of toast got stuck in his throat. A few weeks later, a consultant said, “It’s cancer.” He died nine weeks later aged just 47. If I knew then what I know now, I think he would still be alive. 

## **‘What I know now is persistent heartburn is not normal.’** 

It doesn’t mean you have cancer. And short bouts of heartburn, acid reflux, indigestion (it’s all the same thing) can just be related to having a meal too late one night; eating on the run; overindulging. 

## **But, if it keeps coming back, or you, your partner, or a family member or friend regularly buy over the counter or off-the-shelf treatments, you MUST speak to your doctor and get it checked out, properly.** 

## **And go back again if you keep having a problem.** 

For the last 20 years, I’ve been determined to do what I can to help other families avoid the tragedy that hit mine - so very hard. 

8,000 people a year die of cancer of the oesophagus, often because they didn’t know the warning signs or realise that many cases are preventable. 

Cancer of the oesophagus is the UK’s 7th most deadly cancer, and the 4th most common cause of cancer death in men. 

The incidence is growing here, in the Western world, for reasons we’re not entirely sure of yet, but which might be connected to more inactivity, worse diets and bigger waistlines. 

There are no survival statistics for stage four metastatic oesophageal cancer, which has spread away from the original site. The only chance we have is catching it early. 

We will continue **demanding hope, demanding change** for the future - in the name of those we've lost. 

## **Mimi McCord, Founder and Chairman** 

Page 2 



**HEARTBURN CANCER UK** 

**REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

## **Who We Are** 

We are Heartburn Cancer UK. The country’s leading specialist Barrett’s oesophagus and oesophageal cancer charity. 

Our charity promotes more **awareness** of the symptoms of oesophageal cancer and is demanding more action for oesophageal cancer survival. 

We want every adult in the country to know that persistent heartburn is not normal and long-term selfmedicating isn’t a good solution. 

We want a Barrett’s diagnosis to be seen as a gift. 

We provide trusted information and support those diagnosed with Barrett’s or OC and their loved ones. 

Our aim is for them to have **support** so they do not to feel lost or alone - whatever their diagnosis is. 

We work with a network of people to keep more people alive: with academics, with NHS cancer alliances, with NICE, with medical device developers, with private clinics - anyone who has the same aim as us. 

And we’re increasingly challenging the status quo on behalf of patients. We think they deserve better. We are their advocates, their support, their translators. 

Heartburn Cancer UK is demanding more hope for patients by increasingly supporting **early diagnosis** tools and techniques – such as the capsule sponge test, which we want to see in all UK GP surgeries. 

We stand alongside medical professionals, contribute to medical guidance and support the Surgical Specialist Lead for oesophageal adenocarcinoma who has responsibility both for the development of clinical networks to deliver multi-centre studies as well as ensuring that the studies are relevant to their subspecialty and their patients. These are important areas of **research** which will help improve patient outcomes. 

To mark oesophageal cancer awareness month in February 2024, our **#DemandingHope campaign was highly successful.** 

In a nutshell: 

- Our testing programme was 250% oversubscribed - and we attracted many more men than usual 

- We picked up twice as many positive cases as usual 

- We created a potential a template for future studies 

We recently won a Third Sector Award for it… the ‘Small Charity, Big Achiever’ award which we are very proud of. And we’re now looking at ways we can build on this work in the year ahead. 

We are already working with cancer alliances for regional campaigns for Feb 25. And we are developing an app to further support patients. 

We’re only small, but as you can see, we’re making a big impact, and we’re 100% committed. 

Page 3 



**HEARTBURN CANCER UK REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

## **Our Mission and Focus** 

To be a respected UK source of awareness and information on the risks of ignoring persistent heartburn, encouraging the public to seek medical advice, to champion research to enable an earlier diagnosis to save lives, and to support those living with reflux, Barrett’s oesophagus and oesophageal cancer. 

Page 4 



**HEARTBURN CANCER UK** 

**REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

## **Our 23/24 Highlights** 

We are strongly continuing to highlight the focus of the charity to raise awareness of the possible dangers of ignoring persistent heartburn and its link to Barrett’s and oesophageal cancer.  This will enable an earlier diagnosis of cancer when curative treatment is still possible.  In the 20 plus years of the charity’s existence the prognosis for this cancer remains appalling. 

## **Demanding Hope Campaign** 

A particular highlight has been our Demanding Hope Campaign.  This has been an exceptionally successful collaboration with Cyted Health, The Cleveland Clinic and The Lanesborough hotel in February 2024 for Oesophageal Cancer Awareness Month.  We raised significant awareness and carried out a self-referral capsule sponge testing campaign which included: 

- Successfully executing a self-referral campaign for capsule sponge testing using our mobile unit 

- Cyted Health providing test and pathology 

- The Cleveland Clinic providing medical expertise, follow up and a related research paper published in Frontline Gastroenterology. 

- The Lanesborough providing the unique high visibility site 

- Providing online self-referral triage and appointments 

- Promoting our message through SAGA magazine, LTDA, social media, Press and passing footfall and general traffic at Hyde Park Corner in excess of a month 

- Being 250% oversubscribed for the test and being particularly successful at attracting men. 

- Picking up twice as many positive tests than usual. 

## **HCUK’s 20[th] Anniversary** 

2023 was the 20th anniversary of the charity and as intended we exploited this milestone through our Demanding Hope campaign, adventure challenges, major charity events and use of media opportunities.  These included: 

## Fundraisers 

- Tobias Lands' End to John O’Groats Walk 

- Paris to London Cycle Johnny McCord and Joe Walker 

- Afterburn triple challenge 12 hr fitness marathon, three peaks and Great South Run Kate McCord and team 

- Skydive a number of participants led by the Packers including Tim Underwood 

- London Marathon participant from DOC Cleaning 

- 214 Peak Lake District Challenge for Clara by Peter Dixon 

## Major Charity Events 

- 20th Anniversary Dinner at Evolution London 

## Media and publication successes 

- In excess of 30 pieces of media coverage from our Demanding Hope campaign resulting in 4.15 million+ online readership (470m audience) 

- Numerous publications including SAGA Magazine, LTDA TAXI newspaper and member letter 

- Mirror exclusive with Mimi’s story 

- Sun exclusive on Cyted Led UGI collaboration seeking action with a parliamentary event and delivery of a letter to No 10 

Page 5 



**HEARTBURN CANCER UK** 

**REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

## **Earlier Diagnosis and our Mobile Diagnostic Units** 

Our second MDU was built and used for the first time in our Demanding Hope campaign as a clinical space and awareness billboard at Hyde Park Corner. 

Successful completion of our collaboration with the DELTA capsule sponge project and our MDU being used at three primary care sites/community settings which included some self-referrals.   HCUK also fulfilled a supportive role in PPIE (Patient and Public involvement and Engagement) as part of the advisory board. There is further interest in using the unit from Integrated Care Boards (ICBs) and Cancer Alliances.  We have continued to work on primary care capsule sponge initiatives with Cyted Health through Cytoprime 1 and 2 with a Cytoprime 3 proposal waiting for a decision. 

## **Awareness** 

Social media and our website continue to form a major element of HCUK’s awareness work and trusted information. The HCUK website continues to develop and widen our exposure using the various optimisation tools available.  Social media channels were and continue to be exploited to their maximum potential with available resources.  This has significantly increased our ability to support patients and carers impacted by Barrett’s and Oesophageal Cancer. 

## **Support** 

We established a further support group based at Chase Farm for patients living with Oesophageal Adenocarcinoma (OAC) and our online group continued to grow and develop to include expert speaker sessions. 

## **Trusted Information** 

We added to our video library and developed a new website with clinically checked information to ensure an up-to-date resource for patients and any interested parties. 

Our literature expanded to include information for ‘newly diagnosed’ patients with Barrett’s and OAC and is available via the website, as a down-loadable PDF or as a leaflet that can be sent. All our information is checked by our clinical experts who have ensure accuracy, and patients gave their thoughts on content and readability. 

## **Awareness** 

Costello Medical worked with us on a pro-bono project to help provide robust information on our communication and awareness activities and helped develop a proposal and identity for future awareness campaigns.  They are likely to continue supporting us and stay working with us as we continue to deliver these campaigns. 

## **Research** 

We continued to support several research initiatives that might improve earlier diagnosis or patient outcomes.  This included supporting the Royal College of Surgeons Surgical Speciality Lead role and helping to fund the increased number of endoscopies required following our self-referral campaign in London. 

## **The Team** 

It became a necessity to increase the team of three part time staff to an additional two members and buy-in further expertise on PR and video production.  This will enable the charity to continue in its everincreasing upward progress. 

Page 7 



**HEARTBURN CANCER UK** 

**REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

## **Public benefit** 

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake. 

## **Financial Summary – FY23/24** 

## **Financial Performance Review** 

This financial year has been very positive. With fundraising including a Lands End to John O’Groats Walk, a London to Paris bike ride and our November Anniversary Dinner. Our supporters are always committed to helping us and this year has been a real tribute to our 20th year. 

We have been able to progress HCUK’s work with a new website, printed literature for patients and their loved ones and been able to successfully run our #Demanding Hope Campaign in February – oesophageal cancer awareness month. 

We are also very fortunate to have been supported by Costello Medical who provided pro-bono support for planning our next awareness campaign.  The value of this work was in excess of £30k. This is a relationship which will extend into FY2024/2025. 

## **Income summary** 

Donations streams include our website, fundraisers using the Just Giving platform and those who donate in memory of those who have died as a result of oesophageal cancer. 

Grants applications during our financial year 2023-2024 included our largest single donation to date of 25K from Mike Gooley at Trailfinders. BMS provided funding of £7.5k towards our core costs, among others for which we are very grateful. 

Corporate Partnerships – we are very fortunate to be The Lanesborough hotel’s chosen charity.  All their customer facing services have reference to HCUK and our awareness message and they make a regular donation to us which is a great support to our charitable activity. 

In November 2023 our 20th year celebration dinner and fundraiser, generously sponsored by Loadsure and Tokio Marine Kiln, raised over £33k for HCUK. 

Page 7 



**HEARTBURN CANCER UK** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

Page 8 



**HEARTBURN CANCER UK** 

**REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

## **Fundraising & Income Driving Plans for 2024/2025** 

Beyond the core costs to run the charity, funds raised will be used for: 

- Trusted information for patients, the public and their families - through our various leaflets, website, social channels and through relationships with our growing health care professional contacts nationally 

- Support for patients and their families – responding to questions, in person and online support groups, arranging and hosting expert speaker talks 

- Earlier Diagnosis – continuing to push for the capsule sponge test to be more widely available in primary care and using our mobile unit to partner on community clinics. 

- Research – supporting research that will improve patient outcomes by being a lay representative and patient advocate or partner on research studies and part funding the Surgical Specialist Lead role for the Royal College of Surgeons 

- Patient App - with the help of patients and health care professionals we are planning to develop an app for patients and will designate funds and apply for funding to support this work.  It will provide access to our ‘trusted information’, provide an opportunity to speak to others in the same situation ‘People Like Me’, and will provide an opportunity to ‘Manage My Health’ where patients can record symptoms, appointments etc. 

- General awareness and awareness campaigns – we are working with various Cancer Alliances to pilot our new campaign in at least two areas which we will designate funds to for Feb 25 Oesophageal Cancer Awareness Month 

Page 9 



**HEARTBURN CANCER UK** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

|**Activity**|**Cost Estimate**|**Income Estimate**|**Timeline**|
|---|---|---|---|
|**Just Giving**and**Text Giving**<br>(individual fundraising activities)<br>**Run for charity**activities (Run for<br>charity membership)|Just giving 5%<br>transaction fee<br>£750 Membership|£75,000|Annual|
|**Website**income, including**regular**<br>giving,**ad hoc**donations, website<br>**appeals**, fundraising pages and**shop**<br>purchases|Stripe 2.2% transaction<br>fee (website)|£30,000|Annual|
|**Other**fundraising activities (inc<br>donation cheques etc)|Nil|£26,000||
|**Legacy and in Memoriam**(Much<br>loved tributes, giving in memory)|£650|£25,000|Annual|
|**Direct**to bank donations|Nil|£3,000|Annual|
|**Grant**and**Funder**income|£8,640|£45,000|Annual|
|Maintain our**corporate**relationship|Nil|£25,000|By -monthly and<br>ad hoc|
|**Gift Aid**Tax from Website donations|Nil|£5,000|Annual|
|Bank**Interest**|Nil|£4,000|Annual|
|**TOTAL**||**£238,000**||



Page 10 



**HEARTBURN CANCER UK** 

**REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2024** 

## **Reserves Policy** 

It is the policy of the charity that unrestricted funds, which have not been designated for a specific use should be maintained at a level equivalent to six months expenditure, which is calculated to be in the region of £45k. 

The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity’s current activities whilst consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year. 

## **Risks** 

The Trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to the major risks. 

## **Structure, governance and management** 

The following served as trustees during the year: 

Mrs M E McCord Prof R C Fitzgerald Prof T Underwood Mrs B A Huntingdon Dr O J Stovin Mr W Mathers Mr M Farrier Mrs J Stevenson Timini 

The above are also Directors for the purposes of company law. 

The Board have the statutory power to appoint new trustees under the terms of the Trust Deed and provide the necessary training in order that they may fulfil their obligations as Trustees. 

None of the Trustees has any beneficial interest in the company.  The Directors are members of the company and guarantee to contribute £1 in the event of a winding up. 

The charity is governed by the Board of Trustees which is responsible for formulating the strategies and policies of the charity including exercising financial controls. 

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption. 

28 Jan 2025 

Approved by order of the board of trustees on ………………………….. and signed on its behalf by: 

..................................................................... Mrs M E McCord - Trustee 

Page 11 



**HEARTBURN CANCER UK** 

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES FOR THE YEAR ENDED 30 APRIL 2024** 

The trustees (who are also the directors of Heartburn Cancer UK for the purposes of company law) are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the Charity SORP; 

- make judgements and estimates that are reasonable and prudent; 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business. 

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

Page 12 



**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF HEARTBURN CANCER UK** 

## **Independent examiner's report to the trustees of Heartburn Cancer UK ('the Company')** 

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 April 2024. 

## **Responsibilities and basis of report** 

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). 

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act. 

## **Independent examiner's statement** 

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies. 

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe: 

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or 

3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or 

4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)). 

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. 

N R Whitemore FCCA The Association of Chartered Certified Accountants 

Hopper Williams & Bell Limited Chartered Accountants Highland House Mayflower Close Chandler's Ford Eastleigh Hampshire SO53 4AR 

29 Jan 2025 Date: ............................................. 

Page 13 



**HEARTBURN CANCER UK** 

## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 APRIL 2024** 

|Unrestricted<br>Restricted<br>fund<br>funds<br>Notes<br>£<br>£<br>**INCOME AND ENDOWMENTS FROM**<br>Donations and legacies<br>2<br>**211,307**<br>**60,023**<br>**Charitable activities**<br>5<br>Other charitable activities<br>**-**<br>**-**<br>Other trading activities<br>3<br>**85**<br>**-**<br>Investment income<br>4<br>**3,650**<br>**-**<br>Other income<br>**672**<br>**-**<br>**Total**<br>**215,714**<br>**60,023**<br>**EXPENDITURE ON**<br>Raising funds<br>6<br>**23,101**<br>**-**<br>**Charitable activities**<br>7<br>Early diagnosis<br>**31,520**<br>**31,475**<br>Awareness<br>**45,516**<br>**2,210**<br>Research and education<br>**15,511**<br>**-**<br>Support<br>**35,345**<br>**9,432**<br>Charity running costs<br>**41,024**<br>**-**<br>Other charitable activities<br>**-**<br>**-**<br>**Total**<br>**192,017**<br>**43,117**<br>**NET INCOME**<br>**23,697**<br>**16,906**<br>**Transfers between funds**<br>17<br>**(1,343)**<br>**1,343**<br>**Net movement in funds**<br>**22,354**<br>**18,249**<br>**RECONCILIATION OF FUNDS**<br>Total funds brought forward<br>**88,081**<br>**129,256**<br>**TOTAL FUNDS CARRIED FORWARD**<br>**110,435**<br>**147,505**|**2024**<br>**Total**<br>**funds**<br>**£**<br>**271,330**<br>**-**<br>**85**<br>**3,650**<br>**672**<br>**275,737**<br>**23,101**<br>**62,995**<br>**47,726**<br>**15,511**<br>**44,777**<br>**41,024**<br>**-**<br>**235,134**<br>**40,603**<br>**-**<br>**40,603**<br>**217,337**<br>**257,940**|2023<br>Total<br>funds<br>£<br>153,904<br>19,840<br>225<br>944<br>-|
|---|---|---|
|||174,913|
|||17,757<br>28,096<br>22,301<br>7,245<br>18,113<br>22,308<br>-|
|||115,820|
|||59,093<br>-|
|||59,093<br>158,244|
|||217,337|



The notes form part of these financial statements 

Page 14 



**HEARTBURN CANCER UK** 

## **BALANCE SHEET 30 APRIL 2024** 

|Unrestricted<br>Restricted<br>fund<br>funds<br>Notes<br>£<br>£<br>**FIXED ASSETS**<br>Tangible assets<br>14<br>**-**<br>**52,101**<br>**CURRENT ASSETS**<br>Debtors<br>15<br>**2,896**<br>**-**<br>Cash at bank<br>**111,099**<br>**95,404**<br>**113,995**<br>**95,404**<br>**CREDITORS**<br>Amounts falling due within one year<br>16<br>**(3,560)**<br>**-**<br>**NET CURRENT ASSETS**<br>**110,435**<br>**95,404**<br>**TOTAL ASSETS LESS CURRENT**<br>**LIABILITIES**<br>**110,435**<br>**147,505**<br>**NET ASSETS**<br>**110,435**<br>**147,505**<br>**FUNDS**<br>17<br>Unrestricted funds<br>Restricted funds<br>**TOTAL FUNDS**|**2024**<br>**Total**<br>**funds**<br>**£**<br>**52,101**<br>**2,896**<br>**206,503**<br>**209,399**<br>**(3,560)**<br>**205,839**<br>**257,940**<br>**257,940**<br>**110,435**<br>**147,505**<br>**257,940**|2023<br>Total<br>funds<br>£<br>16,234<br>12,168<br>191,435<br>203,603<br>(2,500)<br>201,103<br>217,337<br>217,337<br>88,081<br>129,256<br>217,337|
|---|---|---|



The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024. 

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006. 

The trustees acknowledge their responsibilities for 

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and 

- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company. 

The notes form part of these financial statements 

Page 15 

continued... 



**HEARTBURN CANCER UK** 

**BALANCE SHEET - continued 30 APRIL 2024** 

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime. 

28 Jan 2025 The financial statements were approved by the Board of Trustees and authorised for issue on ………………………… and were signed on its behalf by: 

............................................. M E McCord - Trustee 

The notes form part of these financial statements 

Page 16 



**HEARTBURN CANCER UK** 

**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2024** 

## **1. ACCOUNTING POLICIES** 

## **Basis of preparing the financial statements** 

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention. 

## **Financial reporting standard 102 - reduced disclosure exemptions** 

The charitable company has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland': 

- the requirements of Section 7 Statement of Cash Flows. 

## **Income** 

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received. 

Donations by way of grants are recognised either on receipt or Invoice, whichever is earlier. Donations and associated gift aid from on-line sites such as Just Giving and Virgin Giving are recognised as and when paid by those sites, after they have been verified and processed, and includes donations remitted to the charity from those sites within the financial year. These donations are recorded net of processing charges. 

Other donations and legacies are recognised on receipt. Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of the donation. 

Donated services and facilities are included in the Statement of Financial Activities in the year they are received at the value of the gift to the charity, provided the value of the gift can be measured reliably. 

The expense element of such donations is reflected in resources expended in the appropriate expense category. 

## **Expenditure** 

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. 

## **Tangible fixed assets** 

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. 

Plant and machinery 

- 

Straight line over 5 years 

Tangible fixed assets are stated at cost less depreciation. Cost represents purchase price together with any incidental costs of acquisition. 

## **Taxation** 

The charity is exempt from corporation tax on its charitable activities. 

## **Fund accounting** 

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. 

continued... 

Page 17 



**HEARTBURN CANCER UK** 

**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

## **1. ACCOUNTING POLICIES - continued** 

## **Fund accounting** 

Restricted funds can only be used for particular restricted purposes within the objects of the charity.  Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. 

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. 

## **Pension costs and other post-retirement benefits** 

The charitable company operates a defined contribution pension scheme.  Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate. 

## **Going concern** 

At the time of preparing the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements. 

## **Financial instruments** 

The charitable company only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measure at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method. 

## **2. DONATIONS AND LEGACIES** 

|Donations and gifts<br>Donations in kind<br>Grants<br>Grants received, included in the above, are as follows:<br>Other grants|**2024**<br>**£**<br>**189,030**<br>**40,800**<br>**41,500**<br>**271,330**<br>**2024**<br>**£**<br>**41,500**|2023<br>£<br>124,904<br>9,000<br>20,000|2023<br>£<br>124,904<br>9,000<br>20,000|
|---|---|---|---|
|||153,904||
||||2023<br>£<br>20,000|



continued... 

Page 18 



**HEARTBURN CANCER UK** 

**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

|**3.**<br>**OTHER TRADING ACTIVITIES**<br>Sale of merchandise<br>**4.**<br>**INVESTMENT INCOME**<br>Deposit account interest<br>**5.**<br>**INCOME FROM CHARITABLE ACTIVITIES**<br>Activity<br>Golf day income<br>Other charitable activities<br>Other<br>Other charitable activities<br>**6.**<br>**RAISING FUNDS**<br>**Raising donations and legacies**<br>Staff costs<br>Website and social media<br>General fundraising costs<br>Travel and training costs<br>Office expenses<br>Printing, post and advertising<br>Golf day event costs<br>Computer expenses<br>Subscriptions<br>Publications and PR<br>Research<br>Outsourcing costs||
|---|---|
|||



continued... 

Page 19 



**HEARTBURN CANCER UK** 

## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

## **7. CHARITABLE ACTIVITIES COSTS** 

|Direct<br>Support<br>Costs (see<br>costs (see<br>note 8)<br>note 9)<br>£<br>£<br>Early diagnosis<br>**62,995**<br>**-**<br>Awareness<br>**47,726**<br>**-**<br>Research and education<br>**15,511**<br>**-**<br>Support<br>**44,777**<br>**-**<br>Charity running costs<br>**35,116**<br>**5,908**<br>**206,125**<br>**5,908**<br>**8.**<br>**DIRECT COSTS OF CHARITABLE ACTIVITIES**<br>**2024**<br>**£**<br>Staff costs<br>**82,462**<br>Office expenses<br>**9,208**<br>Computer expenses<br>**1,217**<br>Printing, post and advertising<br>**3,171**<br>Website and social media<br>**22,556**<br>Sundries<br>**1,014**<br>Insurance<br>**190**<br>Consumables<br>**-**<br>Subscriptions<br>**190**<br>Travel and training costs<br>**3,219**<br>Publications and PR<br>**42,639**<br>MDU maintenance<br>**8,213**<br>Outsourcing costs<br>**14,792**<br>Research<br>**7,129**<br>Depreciation<br>**10,000**<br>Interest payable and similar charges<br>**125**<br>**206,125**|Totals<br>£<br>**62,995**<br>**47,726**<br>**15,511**<br>**44,777**<br>**41,024**|
|---|---|
||**212,033**|
||2023<br>£<br>61,087<br>9,179<br>3,003<br>1,785<br>11,545<br>141<br>1,221<br>819<br>-<br>574<br>-<br>-<br>-<br>-<br>5,412<br>153|
||94,919|



continued... 

Page 20 



**HEARTBURN CANCER UK** 

**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

## **9. SUPPORT COSTS** 

|Charity running costs<br>**10.**<br>**NET INCOME/(EXPENDITURE)**<br>Net income/(expenditure) is stated after charging/(crediting):<br>Depreciation - owned assets<br>Independent examiner's costs<br>**11.**<br>**TRUSTEES' REMUNERATION AND BENEFITS**|Governance<br>costs<br>£<br>**5,908**<br>**2024**<br>2023<br>**£**<br>£<br>**10,000**<br>5,412<br>**1,190**<br>1,135|Governance<br>costs<br>£<br>**5,908**<br>**2024**<br>2023<br>**£**<br>£<br>**10,000**<br>5,412<br>**1,190**<br>1,135|Governance<br>costs<br>£<br>**5,908**<br>**2024**<br>2023<br>**£**<br>£<br>**10,000**<br>5,412<br>**1,190**<br>1,135|
|---|---|---|---|
||||2023<br>£<br>5,412<br>1,135|
|||||



There were no trustees' remuneration or other benefits for the year ended 30 April 2024 nor for the year ended 30 April 2023. 

## **Trustees' expenses** 

During the period ended 30 April 2024, expenses totalling £506 were reimbursed directly to one Trustee  (2023: none). 

## **12. STAFF COSTS** 

|Wages and salaries<br>Other pension costs<br>The average monthly number of employees during the year was as follows:<br>Administration|**2024**<br>**£**<br>**84,584**<br>**2,218**<br>**86,802**<br>**2024**<br>**3**|2023<br>£<br>62,761<br>1,541|
|---|---|---|
|||64,302|
|||2023<br>3|



No staff receive more than £60,000 per annum either this year or the prior year. 

continued... 

Page 21 



**HEARTBURN CANCER UK** 

## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

|**13.**<br>**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**<br>Unrestricted<br>Restricted<br>fund<br>funds<br>£<br>£<br>**INCOME AND ENDOWMENTS FROM**<br>Donations and legacies<br>71,609<br>82,295<br>**Charitable activities**<br>Other charitable activities<br>18,810<br>1,030<br>Other trading activities<br>225<br>-<br>Investment income<br>944<br>-<br>**Total**<br>91,588<br>83,325<br>**EXPENDITURE ON**<br>Raising funds<br>17,757<br>-<br>**Charitable activities**<br>Early diagnosis<br>-<br>28,096<br>Awareness<br>22,301<br>-<br>Research and education<br>7,245<br>-<br>Support<br>18,113<br>-<br>Charity running costs<br>22,308<br>-<br>Other charitable activities<br>-<br>-<br>**Total**<br>87,724<br>28,096<br>**NET INCOME**<br>3,864<br>55,229<br>**RECONCILIATION OF FUNDS**<br>Total funds brought forward<br>84,221<br>74,023<br>**TOTAL FUNDS CARRIED FORWARD**<br>88,085<br>129,252|Total<br>funds<br>£<br>153,904<br>19,840<br>225<br>944|
|---|---|
||174,913|
||17,757<br>28,096<br>22,301<br>7,245<br>18,113<br>22,308<br>-|
||115,820|
||59,093<br>158,244|
||217,337|



continued... 

Page 22 



**HEARTBURN CANCER UK** 

**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

## **14. TANGIBLE FIXED ASSETS** 

|**COST**<br>At 1 May 2023<br>Additions<br>At 30 April 2024<br>**DEPRECIATION**<br>At 1 May 2023<br>Charge for year<br>At 30 April 2024<br>**NET BOOK VALUE**<br>At 30 April 2024<br>At 30 April 2023<br>**15.**<br>**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**<br>Prepayments and accrued income<br>**16.**<br>**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**<br>Accruals and deferred income||Plant and<br>machinery<br>£<br>**27,058**<br>**45,867**<br>**72,925**<br>**10,824**<br>**10,000**<br>**20,824**<br>**52,101**<br>16,234<br>**2024**<br>2023<br>**£**<br>£<br>**2,896**<br>12,168<br>**2024**<br>2023<br>**£**<br>£<br>**3,560**<br>2,500|Plant and<br>machinery<br>£<br>**27,058**<br>**45,867**<br>**72,925**<br>**10,824**<br>**10,000**<br>**20,824**<br>**52,101**<br>16,234<br>**2024**<br>2023<br>**£**<br>£<br>**2,896**<br>12,168<br>**2024**<br>2023<br>**£**<br>£<br>**3,560**<br>2,500|Plant and<br>machinery<br>£<br>**27,058**<br>**45,867**<br>**72,925**<br>**10,824**<br>**10,000**<br>**20,824**<br>**52,101**<br>16,234<br>**2024**<br>2023<br>**£**<br>£<br>**2,896**<br>12,168<br>**2024**<br>2023<br>**£**<br>£<br>**3,560**<br>2,500|
|---|---|---|---|---|
||||**72,925**||
||||**10,824**<br>**10,000**||
||||**20,824**||
||||**52,101**||
||||16,234||
||||2023<br>£<br>12,168||
|||||2023<br>£<br>2,500|



continued... 

Page 23 



**HEARTBURN CANCER UK** 

## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

## **17. MOVEMENT IN FUNDS** 

|**MOVEMENT IN FUNDS**|||||
|---|---|---|---|---|
|||Net|Transfers||
|||movement|between||
||At 1.5.23|in funds|funds|At 30.4.24|
||£|£|£|£|
|**Unrestricted funds**|||||
|General fund|**88,081**|**23,697**|**(1,343)**|**110,435**|
|**Restricted funds**|||||
|Cytosponge Mobile Diagnostic Unit -|||||
|operation|**76,212**|**32,713**|**(56,824)**|**52,101**|
|Cytosponge Mobile Diagnostic Unit -|||||
|purchase|**17,156**|**(5,412)**|**(11,744)**|**-**|
|Return to fitness|**1,000**|**(67)**|**-**|**933**|
|Awareness - North West of England|**2,102**|**-**|**-**|**2,102**|
|Awareness - London|**500**|**-**|**-**|**500**|
|HCUK East Anglia|**2,151**|**-**|**-**|**2,151**|
|Awareness|**-**|**(1,343)**|**1,343**|**-**|
|Core costs|**8,000**|**-**|**-**|**8,000**|
|Support project|**12,000**|**(9,575)**|**-**|**2,425**|
|Early diagnosis|**10,135**|**-**|**(10,135)**|**-**|
|London Support Group|**-**|**590**|**-**|**590**|
|MDU service|**-**|**-**|**78,703**|**78,703**|
||**129,256**|**16,906**|**1,343**|**147,505**|
|**TOTAL FUNDS**|**217,337**|**40,603**|**-**|**257,940**|
|Net movement in funds, included in the above are as follows:|||||
|||Incoming|Resources|Movement|
|||resources|expended|in funds|
|||£|£|£|
|**Unrestricted funds**|||||
|General fund||**215,714**|**(192,017)**|**23,697**|
|**Restricted funds**|||||
|Cytosponge Mobile Diagnostic Unit -|||||
|operation||**58,566**|**(25,853)**|**32,713**|
|Cytosponge Mobile Diagnostic Unit -|||||
|purchase||**-**|**(5,412)**|**(5,412)**|
|Return to fitness||**-**|**(67)**|**(67)**|
|Awareness||**867**|**(2,210)**|**(1,343)**|
|Support project||**-**|**(9,575)**|**(9,575)**|
|London Support Group||**590**|**-**|**590**|
|||**60,023**|**(43,117)**|**16,906**|
|**TOTAL FUNDS**||**275,737**|**(235,134)**|**40,603**|



continued... 

Page 24 



**HEARTBURN CANCER UK** 

**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

## **17. MOVEMENT IN FUNDS - continued** 

## **Comparatives for movement in funds** 

|||Net||
|---|---|---|---|
|||movement||
||At 1.5.22|in funds|At 30.4.23|
||£|£|£|
|**Unrestricted funds**||||
|General fund|84,221|3,860|88,081|
|**Restricted funds**||||
|Cytosponge Mobile Diagnostic Unit -||||
|operation|41,114|35,098|76,212|
|Cytosponge Mobile Diagnostic Unit - Essex||||
|& Suffolk|10,000|(10,000)|-|
|Cytosponge Mobile Diagnostic Unit -||||
|purchase|17,156|-|17,156|
|Return to fitness|1,000|-|1,000|
|Awareness - North West of England|2,102|-|2,102|
|Awareness - London|500|-|500|
|HCUK East Anglia|2,151|-|2,151|
|Core costs|-|8,000|8,000|
|Support project|-|12,000|12,000|
|Early diagnosis|-|10,135|10,135|
||74,023|55,233|129,256|
|**TOTAL FUNDS**|158,244|59,093|217,337|
|Comparative net movement in funds, included in the above are as follows:||||
||Incoming|Resources|Movement|
||resources|expended|in funds|
||£|£|£|
|**Unrestricted funds**||||
|General fund|91,588|(87,728)|3,860|
|**Restricted funds**||||
|Cytosponge Mobile Diagnostic Unit -||||
|operation|53,190|(18,092)|35,098|
|Cytosponge Mobile Diagnostic Unit - Essex||||
|& Suffolk|-|(10,000)|(10,000)|
|Core costs|8,000|-|8,000|
|Support project|12,000|-|12,000|
|Early diagnosis|10,135|-|10,135|
||83,325|(28,092)|55,233|
|**TOTAL FUNDS**|174,913|(115,820)|59,093|



Page 25 

continued... 



**HEARTBURN CANCER UK** 

**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

## **17. MOVEMENT IN FUNDS - continued** 

## **Cytosponge Mobile Diagnostic Unit - operation** 

To fund the purchase of a Mobile Diagnostic Unit and related equipment, which are accounted for as fixed assets and is being depreciated from May 2021, and fund the running costs of the unit.  The unit is currently being deployed to support the DELTA project to demonstrate the  efficacy of the "Cytosponge" in promoting early diagnosis of Oesophageal Cancer and/or Barrett's Oesophagus. For ease in this financial year and going forward, this fund has been amalgamated as MDU Service. 

## **Cytosponge Mobile Diagnostic Unit - purchase** 

Funds raising from the Golf Day event arranged to fund the purchase of an additional Mobile Diagnostic Unit and related equipment, which are accounted for as fixed assets and is being depreciated from Nov 2023. For ease in this financial year and going forward, this fund has been amalgamated as MDU Service. 

## **Return to fitness** 

To support a research project into a programme to support Oesophageal Cancer patients recovering after treatment. 

## **Awareness - North West of England** 

Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus, in the North West of England. 

## **Awareness- London** 

Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus, in the London area. 

## **Awareness** 

Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus. 

## **HCUK East Anglia** 

To fund the activities of the East Anglia support group with funds generated by the support group itself. 

## **Core costs** 

Funds to support the core costs of the charity. 

## **Support projects** 

Funds to support ongoing projects. 

## **Early diagnosis** 

Funds to support early diagnosis of Oesophageal Cancer and/or Barrett's Oesophagus. For ease in this financial year and going forward, this fund has been amalgamated as MDU Service. 

## **London Support Group** 

This fund is money which has been granted to us for Heartburn's support projects. This project is ongoing and includes everything related to being able to provide up to date, accessible and efficient support  to Heartburn's community, i.e. the changes and updates to our website to make it more user friendly with current, clinically verified information, literature (both printed and online) for patients and carers to support their  journey with persistent heartburn, Barrett's and oesophageal cancer and all related symptoms, conditions and treatments. 

## **MDU Service** 

In previous years Heartburn have had several categories for Early Diagnosis funds. These 

Page 26 

continued... 



**HEARTBURN CANCER UK** 

**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024** 

## **17. MOVEMENT IN FUNDS - continued** 

have all been for our Mobile Diagnostic Units but under different fund names, Cytosponge Mobile Diagnostic Unit - operation, Cytosponge Mobile Diagnostic Unit - purchase, and Early diagnosis. For ease in this financial year and going forward, these funds have been amalgamated as MDU Service. 

## **18. RELATED PARTY DISCLOSURES** 

During the year Absolutely Offices Limited, of which Beryl Huntingdon, a trustee of the charitable company, is a director, provided office services to the charity on normal commercial terms totalling £1,410 (2023: £1,032). 

In addition Absolutely Offices Limited provided the office space free of charge as a donation in kind and has been accounted for within donations totalling £9,000 (2023: £9,000). 

Page 27 

